Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × Advanced Cancers × Clear all

Phase

Phase 1 2 Phase 1/2 1

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 136 Neoplasms 98 Breast Neoplasms 76 Colorectal Neoplasms 75 Leukemia, Myeloid, Acute 71 Pancreatic Neoplasms 70 Recurrence 66 Neoplasm Metastasis 66 Melanoma 65 Multiple Myeloma 61 Prostatic Neoplasms 60 Ovarian Neoplasms 60 Stomach Neoplasms 53 Lung Neoplasms 47 Squamous Cell Carcinoma of Head and Neck 46 Lymphoma 43 Advanced Solid Tumor 42 Precursor Cell Lymphoblastic Leukemia-Lymphoma 41 Triple Negative Breast Neoplasms 40 Glioblastoma 40 Lymphoma, Non-Hodgkin 37 Endometrial Neoplasms 37 Uterine Cervical Neoplasms 32 Carcinoma, Renal Cell 31 Carcinoma, Hepatocellular 31 Advanced Solid Tumors 29 Brain Neoplasms 28 Small Cell Lung Carcinoma 26 Sarcoma 26 Lymphoma, Large B-Cell, Diffuse 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03375983 2024-02-20

Plasmodium Immunotherapy for Advanced Cancers

CAS Lamvac Biotech Co., Ltd.

Phase 1/2 Recruiting

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡